The MAPK pathway as an apoptosis enhancer in melanoma

被引:32
|
作者
Haydn, Johannes M. [1 ]
Hufnagel, Anita [1 ]
Grimm, Johannes [1 ]
Maurus, Katja [1 ]
Schartl, Manfred [1 ,2 ]
Meierjohann, Svenja [1 ,2 ]
机构
[1] Univ Wurzburg, Bioctr, Dept Physiol Chem, D-97070 Wurzburg, Germany
[2] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
关键词
Crosstalk; chemotherapy resistance; RAS; PI3K; melanoma; MEK INHIBITION; BRAF(V600E) INHIBITION; ACQUIRED-RESISTANCE; INDUCED ACTIVATION; IMPROVED SURVIVAL; DISTINCT ROLES; RAF INHIBITION; OPEN-LABEL; BRAF; RECEPTOR;
D O I
10.18632/oncotarget.2079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inhibition of RAF/MEK/ERK signaling is beneficial for many patients with BRAFV600E-mutated melanoma. However, primary and secondary resistances restrict long-lasting therapy success. Combination therapies are therefore urgently needed. Here, we evaluate the cellular effect of combining a MEK inhibitor with a genotoxic apoptosis inducer. Strikingly, we observed that an activated MAPK pathway promotes in several melanoma cell lines the pro-apoptotic response to genotoxic stress, and MEK inhibition reduces intrinsic apoptosis. This goes along with MEK inhibitor induced increased RAS and P-AKT levels. The protective effect of the MEK inhibitor depends on PI3K signaling, which prevents the induction of pro-apoptotic PUMA that mediates apoptosis after DNA damage. We could show that the MEK inhibitor dependent feedback loop is enabled by several factors, including EGF receptor and members of the SPRED family. The simultaneous knockdown of SPRED1 and SPRED2 mimicked the effects of MEK inhibitor such as PUMA repression and protection from apoptosis. Our data demonstrate that MEK inhibition of BRAFV600E-positive melanoma cells can protect from genotoxic stress, thereby achieving the opposite of the intended anti-tumorigenic effect of the combination of MEK inhibitor with inducers of intrinsic apoptosis.
引用
收藏
页码:5040 / 5053
页数:14
相关论文
共 50 条
  • [31] A Comprehensive Analysis of the Effects of MAPK Pathway Inhibition on the Immunological Properties of Melanoma Cells
    Boni, A.
    Fisher, J. L.
    Hampton, T. H.
    Yan, S.
    Tafe, L. J.
    Tsongalis, G. J.
    Turk, M. J.
    Mullins, D. W.
    Brinckerhoff, C. E.
    Fadul, C. E.
    Ernstoff, M. S.
    MODERN PATHOLOGY, 2014, 27 : 130A - 131A
  • [32] Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma
    A Roesch
    Oncogene, 2015, 34 : 2951 - 2957
  • [33] A Comprehensive Analysis of the Effects of MAPK Pathway Inhibition on the Immunological Properties of Melanoma Cells
    Boni, A.
    Fisher, J. L.
    Hampton, T. H.
    Yan, S.
    Tafe, L. J.
    Tsongalis, G. J.
    Turk, M. J.
    Mullins, D. W.
    Brinckerhoff, C. E.
    Fadul, C. E.
    Ernstoff, M. S.
    LABORATORY INVESTIGATION, 2014, 94 : 130A - 131A
  • [34] Molecular dissection of the RAS/RAF/MAPK pathway in primary and metastatic melanoma.
    Rother, J.
    Bailey, J.
    Alvarado, G.
    Prieto, V. G.
    Lazar, A. J.
    Jones, D.
    Hwu, W. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 465S - 465S
  • [35] Design and development of cucurbitacin analogs inhibiting MAPK pathway cascade for the treatment of melanoma
    Ahmed, Mahmoud S.
    Halaweish, Fathi T.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [36] Implications of MAPK pathway inhibition on monocytes and tumor-associated macrophages in melanoma
    Gremel, Gabriela
    Girotti, Maria Romina
    Viros, Amaya
    Ashton, Garry
    Bradley, Helen
    Galvani, Elena
    Lee, Rebecca
    Fusi, Alberto
    Lorigan, Paul
    Marais, Richard
    CANCER RESEARCH, 2015, 75
  • [37] Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma
    Roesch, A.
    ONCOGENE, 2015, 34 (23) : 2951 - 2957
  • [38] Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
    Inamdar, Gajanan S.
    Madhunapantula, SubbaRao V.
    Robertson, Gavin P.
    BIOCHEMICAL PHARMACOLOGY, 2010, 80 (05) : 624 - 637
  • [39] Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics
    Ferraz, Leticia Silva
    da Costa, Renata Torres
    da Costa, Claudia Alves
    Joao Ribeiro, Cesar Augusto
    Arruda, Denise Costa
    Maria-Engler, Silvya Stuchi
    Rodrigues, Tiago
    BIOCHEMICAL PHARMACOLOGY, 2020, 178
  • [40] Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
    Cohen, Justine, V
    Sullivan, Ryan J.
    CLINICAL CANCER RESEARCH, 2019, 25 (19) : 5735 - 5742